Myelodysplastic Syndrome Market to Grow at 10% CAGR to 2019

Feb 02, 2016, 07:30 ET from ReportsnReports

PUNE, India, February 2, 2016 /PRNewswire/ --

For growth of myelodysplastic syndrome market, presence of diagnostic tools is considered a key driver with diagnosis techniques like blood count, peripheral blood smear test, microscopic exams, cytochemistry, flow cytometry and immunotherapy, cytogenetics, FISH, and PCR help in the detection of MDS. Consequently, these diagnostic tools are expected to have a positive impact on the usage of drugs for people suffering from MDS.  The analysts forecast global myelodysplastic syndrome market to grow at a CAGR of 10% during the period 2015-2019.

Complete report on myelodysplastic syndrome market spread across 81 pages, analyzing 3 major companies and providing 45 data exhibits is now available at http://www.reportsnreports.com/reports/461285-global-myelodysplastic-syndrome-market-2015-2019.html.

Government organizations and pharmaceutical companies are conducting awareness programs to spread knowledge about the disease and associated drugs. In addition, they are also providing patient assistance programs to give low-income people with myelodysplastic syndrome access to these drugs. These two factors will surge the number of people availing treatment services, increasing the sales and consumption of drugs.

According to the myelodysplastic syndrome market report, the immune system of an individual deteriorates as aging progresses. For this reason, people aged 60 and above are more susceptible to this disease. A surge in the population of this age group will increase the need for treatment drugs, positively influencing the latter's sales and revenue.

Market research analysts estimate the Americas to dominate the global myelodysplastic syndrome market during the forecast period. Factors like the presence of unmet medical needs in the US coupled with the rise in ageing population in this region are expected to account for this region's high market domination during the forecast period. Order a copy of Global Myelodysplastic Syndrome Market 2015-2019 report @ http://www.reportsnreports.com/Purchase.aspx?name=461285.

Alkylating agents are used to treat different types of cancer and function by attaching an alkyl group to the guanine base of the DNA. Dacogen by Otsuka and Vidaza by Celgene are examples of alkylating agents that are used for the treatment of MDS.

The global myelodysplastic syndrome market is envisaged to grow at a moderate pace due to the high-unmet medical needs of patients, growing public awareness, and the increase in the ageing patient population. Companies that have the ability to manufacture and market drugs that can effectively treat and cure MDS will gain prominence in myelodysplastic syndrome market during the forecast period.

Leading vendors in the global myelodysplastic syndrome market are Celgene, Novartis and Otsuka. Other prominent vendors in this market are Acceleron Pharma, Amgen, Astellas, Astex , Actinium Pharmaceuticals, Bellicum Pharmaceuticals, BioLineRx, Celator Pharmaceuticals, Cornerstone Pharmaceuticals, CTI BioPharma, Eli-lilly, Gamida Cell , GlaxoSmithKline, KaloBios Pharmaceuticals, Kiadis Pharma, Mirati Therapeutics, Onconova Therapeutics, Strategia Therapeutics, Sumitomo Dainippon Pharma , Sunesis Pharmaceuticals, Targazyme, and TetraLogic Pharmaceuticals.

Further, the report states that the high cost of drugs used for treating myelodysplastic syndrome can deter people from consuming them.

Another related report titled Global Acute Coronary Syndrome (ACS) Market 2015-2019 forecasts the Global acute coronary syndrome market to grow at a CAGR of 13.24% over the period 2014-2019. Growing public awareness of ACS is one of the key trends being witnessed in this market. Several organizations are initiating various programs to spread awareness about ACS for the early diagnosis and treatment of the syndrome and to decrease mortality and morbidity from heart attacks. Browse complete report @ http://www.reportsnreports.com/reports/345763-global-acute-coronary-syndrome-acs-market-2015-2019.html.

Key players in the global acute coronary syndrome market are AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc and Sanofi SA. Other Prominent Vendors in the market are AbbVie, Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Merck, Novartis, Pfizer, Portola Pharmaceuticals and Teva Pharmaceutical.

Explore other new reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/.

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:  http: //http://www.reportsnreports.com/feed/l-latestreports.xml


SOURCE ReportsnReports